In our previous study, Th1/Th2 rate in the blood of AML patients significantly decreased, and IRF2 can significantly reduce the ratio of normal and AML patients-derived CD4+ T cells differentiated into Th1/Th2 cells [41]. This evidence concerns the gene IRF2 and acute myeloid leukemia.